Johnson & Johnson’s Icotyde receives US FDA approval for first-line systemic treatment of plaque psoriasis with a targeted oral peptide: Spring House, Pennsylvania Friday, March ...
Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psorias ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results